In a study of aggressive, treatment-naïve advanced prostate cancer assessing BRCA1/2 mutations by whole genome sequencing, a 0.6% BRCA1 and 12% BRCA2 mutation rate was observed, all with biallelic inactivation, and half of which were somatic mutations [18]. The gene discussed is BRCA1; the disease is prostate carcinoma.